Daiichi Sankyo Company, Limited (DSKYF)

29.75 +1.53 (+5.42%) At close: 02:45PM EDT

Daiichi Sankyo Company, Limited

3-5-1, Nihonbashi-honcho
Chuo-ku
Tokyo 103-8426
Japan
81 3 6225 1111
https://www.daiichisankyo.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 17,435

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Sunao Manabe D.V.M., Ph.D.	Group CEO & Executive Chairperson	1.81M	N/A	1954
Mr. Hiroyuki Okuzawa	President, COO & Representative Director	712.69k	N/A	1962
Mr. Masahiko Ohtsuki	Senior Managing Exec. Officer, Head of Global DX, Chief Digital Transformation Officer & Director	712.69k	N/A	1959
Dr. Shoji Hirashima	Senior Managing Executive Officer, Head of Japan Business Unit & Representative Director	771k	N/A	1961
Mr. Koji Ogawa	Managing Executive Officer, Head of Global Corporate Planning & Management and CFO	N/A	N/A	N/A
Chiyu	General Manager of Finance & Accounting Department	N/A	N/A	N/A
Hiroto Kashiwase	Managing Executive Officer, Head of Technology Management HQ and Head of Supply Chain HQ	N/A	N/A	N/A
Naoto Tsukaguchi	Gen. Counsel, Corp. Officer, Head of Global Leg., IP, Global Compl. and Risk & VP of Leg. Aff. Dept.	N/A	N/A	N/A
Kentaro Asakura	Vice President of Corporate Communications Department	N/A	N/A	N/A
Ms. Marielle Cohard-Radice M.D.	Global Head of Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Corporate governance

Daiichi Sankyo Company, Limited’s ISS governance QualityScore as of 1 April 2024 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 2; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.